Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

121. Review: Lithium is associated with adverse events in patients with mood disorders.

Review: Lithium is associated with adverse events in patients with mood disorders. ACP Journal Club. Review: lithium is associated with adverse events in patients with mood disorders. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create (...) File 1 selected item: 22801701 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jul 17;157(2):JC2-10. doi: 10.7326/0003-4819-157-2-201207170-02010. ACP Journal Club. Review: lithium is associated with adverse events in patients with mood disorders. . Comment on [Lancet. 2012] PMID: 22801701 DOI: Publication type Full Text

Annals of Internal Medicine2012

122. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis

Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis Alberton M, Wu P, Druyts E, Briel M, Mills EJ CRD summary The use of statin therapy for cardiovascular disease (...) was associated with a relatively low risk of adverse events. High risk of bias within the studies, high clinical and methodological heterogeneity between the studies, and a discrepancy between the initial outcomes stated and those actually reported suggest that the authors' conclusions and recommendations may not be reliable. Authors' objectives To assess adverse events associated with the use of individual statin treatments for cardiovascular disease. Searching Twelve databases were searched

DARE.2012

123. Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study.

Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. OBJECTIVE: To assess the risk of adverse cardiovascular events in women who discontinue hormone replacement therapy after myocardial infarction compared with those who continue. DESIGN: Nationwide register based cohort study. SETTING: All hospitals in Denmark. POPULATION: All 3322 women aged 40 years or over who survived 30 days after (...) not have a significantly different risk of reinfarction (hazard ratio 0.90, 95% confidence interval 0.68 to 1.19), cardiovascular mortality (1.21, 0.90 to 1.62), or all cause mortality (1.22, 0.97 to 1.53) than women who continued use. However, discontinuation of vaginal oestrogen was associated with a lower risk of reinfarction (hazard ratio 0.54, 0.34 to 0.86). CONCLUSION: No certain conclusions can be drawn regarding increased or decreased risk of adverse cardiovascular events with continuing

BMJ2012 Full Text: Link to full Text with Trip Pro

124. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials Zaccara G, Gangemi P, Perucca P, Specchio L CRD summary The review concluded that individuals starting pregabalin treatment were at increased risk of several adverse (...) events, particularly those affecting cognition/co-ordination, which followed a dose-response relationship. The review was generally well conducted, but the potential issues with trial quality and the small number of trials for some adverse events limit the reliability of the results. Authors' objectives To determine the adverse event profile of pregabalin. Searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to February 2010. Search terms were

DARE.2012

125. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Kwok CS, Nijjar RS, Loke YK CRD summary The authors concluded (...) that proton-pump inhibitors were associated with a reduction in adverse gastrointestinal events (particularly haemorrhages) in patients who were receiving dual antiplatelet therapy (clopidogrel and aspirin). Potential bias in the review process and reliance on lower quality study designs mean that the reliability of this conclusion is uncertain. Authors' objectives To evaluate the effects of proton-pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel. Searching PubMed, EMBASE

DARE.2012

126. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Alves C, Batel-Marques F, Macedo AF CRD summary The review found that the available published evidence was insufficient to support an increased risk of acute (...) -1 agonists. Funding Foundation for Science and Technology (FCT), Portugal. Bibliographic details Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Research and Clinical Practice 2012; 98(2): 271-284 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Diabetes Mellitus, Type 2 /drug therapy; Glucagon-Like Peptide 1 /adverse effects /agonists /analogs

DARE.2012

127. Fingolimod (Gilenya?): not recommended for patients at known risk of cardiovascular adverse events

Fingolimod (Gilenya?): not recommended for patients at known risk of cardiovascular adverse events Fingolimod (Gilenya▼): not recommended for patients at known risk of cardiovascular adverse events Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Fingolimod (Gilenya▼): not recommended for patients at known risk of cardiovascular adverse events From: Published: 22 May 2012 Therapeutic area: New advice for extended early monitoring for those with significant (...) follows further review of world-wide data including 15 cases of sudden or unexplained death with fingolimod. Most of the deaths and cardiovascular events had occurred in patients with either a history of cardiovascular problems, such as atrioventricular block or bradycardia, or those who were also taking other medicines. However the data reviewed were not conclusive as to whether Gilenya was the cause of the deaths. The maximum effect of fingolimod on decreasing the heart rate occurred within six

MHRA Drug Safety Update2012

128. Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy

Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy Verleye L, van de Wetering F, Heus P, Scholten R, Vlayen J Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Verleye L, van de Wetering F, Heus P, Scholten R, Vlayen J. Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 191C. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic

Health Technology Assessment (HTA) Database.2012

129. Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events

Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: second-generation antipsychotics improve response in paediatric bipolar disorder, but are associated with adverse events Article Text Therapeutics Review: second-generation antipsychotics improve response in paediatric bipolar disorder

Evidence-Based Mental Health2012

130. Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events

Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events Article Text

Evidence-Based Medicine (Requires free registration)2012

131. Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use

Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use Article Text Prognosis Use of ADHD drugs in children and young adults does not increase risk of serious

Evidence-Based Mental Health2012

132. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study

Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study 21925636 2011 10 31 2012 01 17 2017 02 20 1097-6868 205 5 2011 Nov American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. 498.e1-6 10.1016/j.ajog.2011.07.011 To describe surgical (...) complications in 597 women over a 24-month period after randomization to retropubic or transobturator midurethral slings. During the Trial of Midurethral Slings study, the Data Safety Monitoring Board regularly reviewed summary reports of all adverse events using the Dindo Surgical Complication Scale. Logistic regression models were created to explore associations between clinicodemographic factors and surgical complications. A total of 383 adverse events were observed among 253 of the 597 women (42

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

134. Evaluating preventable adverse safety events after elective lower extremity procedures

Evaluating preventable adverse safety events after elective lower extremity procedures 21636238 2011 09 05 2011 11 10 2012 10 03 1097-6809 54 3 2011 Sep Journal of vascular surgery J. Vasc. Surg. Evaluating preventable adverse safety events after elective lower extremity procedures. 706-13 10.1016/j.jvs.2011.03.230 Improving patient safety has become a national priority. Patient safety indicators (PSIs) are validated tools to identify potentially preventable adverse events. No studies currently (...) ), hospital teaching status (OR, 1.21; 95% CI, 1.17-1.26), and larger hospitals (OR, 1.11; 95% CI, 1.05-1.17). PSI occurrence was associated with increased cost ($28,387 vs $13,278; P < .0001). Endovascular procedures were found to have lower mortality rates overall, but were found to have a greater number of safety events occur primarily due to bleeding complications in women and the elderly. PSIs were associated with advanced age, black race, and comorbidities. Adverse events added significant cost

EvidenceUpdates2011

135. Emergency hospitalizations for adverse drug events in older americans.

Emergency hospitalizations for adverse drug events in older americans. BACKGROUND: Adverse drug events are important preventable causes of hospitalization in older adults. However, nationally representative data on adverse drug events that result in hospitalization in this population have been limited. METHODS: We used adverse-event data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (2007 through 2009) to estimate the frequency (...) and rates of hospitalization after emergency department visits for adverse drug events in older adults and to assess the contribution of specific medications, including those identified as high-risk or potentially inappropriate by national quality measures. RESULTS: On the basis of 5077 cases identified in our sample, there were an estimated 99,628 emergency hospitalizations (95% confidence interval [CI], 55,531 to 143,724) for adverse drug events in U.S. adults 65 years of age or older each year from

NEJM2011

136. One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events

One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events 21288597 2011 08 29 2011 11 08 2016 11 22 1097-6760 58 3 2011 Sep Annals of emergency medicine Ann Emerg Med One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events. 250-6 10.1016/j.annemergmed.2010.12.021 We investigate the incidence of adverse events at 1 year in the cohort of emergency department (ED) syncope patients (...) enrolled in the original Risk Stratification of Syncope in the Emergency Department (ROSE) study, the time to adverse event, and the test performance of the ROSE decision instrument to detect events at 1 year. This report details the 1-year follow-up of adult syncope patients presenting to the ED who were enrolled into the ROSE study, a single-center, prospective, observational cohort study. The primary endpoint was the combination of serious outcome and all-cause death at 1 year. Serious outcome

EvidenceUpdates2011

137. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis Singh S, Loke YK, Spangler JG, Furberg CD CRD summary This generally well-conducted review concluded that there were safety concerns about the potential (...) for an increased risk of serious adverse cardiovascular events associated with varenicline treatment for tobacco users. This conclusion seems reliable, but the included evidence had limitations that need to be kept in mind. Authors' objectives To determine the incidence of serious adverse cardiovascular events associated with varenicline, compared with placebo, for tobacco use cessation. Searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched, without language

DARE.2011

138. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice.

High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. OBJECTIVE: To examine the prevalence and patterns of high risk prescribing, defined as potentially inappropriate prescribing of drugs to primary care patients particularly vulnerable to adverse drug events. DESIGN: Cross sectional population database analysis. SETTING: General practices in Scotland. PARTICIPANTS: 315 Scottish (...) general practices with 1.76 million registered patients, 139 404 (7.9%) of whom were defined as particularly vulnerable to adverse drug events because of age, comorbidity, or co-prescription. MAIN OUTCOME MEASURES: How reliably each of 15 indicators-four each for non-steroidal anti-inflammatory drugs, co-prescription with warfarin, and prescribing in heart failure, two for dose instructions for methotrexate, and one for antipsychotic prescribing in dementia-and a composite of all 15 could distinguish

BMJ2011

139. Paid malpractice claims for adverse events in inpatient and outpatient settings.

Paid malpractice claims for adverse events in inpatient and outpatient settings. CONTEXT: An analysis of paid malpractice claims may provide insight into the prevalence and seriousness of adverse medical events in the outpatient setting. OBJECTIVE: To report and compare the number, magnitude, and type of paid malpractice claims for events in inpatient and outpatient settings. DESIGN AND SETTING: Retrospective analysis of malpractice claims paid on behalf of physicians in outpatient (...) for events in the inpatient setting, 4448 (43.1%; 95% CI, 42.1%-44.0%) were for events in the outpatient setting, and 966 (9.4%; 95% CI, 8.8%-9.9%) involved events in both settings. The proportion of payments for events in the outpatient setting increased by a small but statistically significant amount, from 41.7% (95% CI, 40.9%-42.6%) in 2005 to 43.1% (95% CI, 42.1%-44.0%) in 2009 (P < .001 for trend across years). In the outpatient setting, the most common reason for a paid claim was diagnostic

JAMA2011

140. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years

Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years (...) or with inactivated influenza vaccine, for children younger than five years, considering the impact of adverse events. The authors concluded that the live attenuated vaccine was similar in cost-effectiveness to the inactivated vaccine, under a wide range of assumptions on the incidence of adverse events. The methods were valid and should ensure that the authors’ conclusions are robust. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective This study assessed the cost

NHS Economic Evaluation Database.2011